3.2. Secondary Outcomes
ADVERSE EVENTS
We did not observe any significant variations in the NEWS2 scores of the lactoferrin vs. placebo groups recorded at 7, 14, and 21 days with respect to baseline. Likewise, we did not detect any lactoferrin effects on the need for oxygen supplementation and its duration, non-invasive or mechanically assisted ventilation, or in-hospital mortality at 14 and 28 days from admission (With regard to the laboratory parameters, we did not record a significant difference in CRP, IL-6, or ferritin plasma concentrations measured at 7 days and 14 days between treatment groups (A subgroup analysis of subjects 65 years or older vs. those younger than 65 years and of females vs. males failed to reveal any effects of lactoferrin on primary outcomes (Lastly, there were no significant differences in the proportion of adverse events between the lactoferrin and placebo arms (